Biosimilar Rituximab
Autoimmune diseases
PreclinicalActive
Key Facts
About Afrigen Biologics
South African biotech delivering affordable vaccines and biosimilars using proprietary biologics platforms.
View full company profileAbout Biosidus
Argentina‑based biosimilar leader delivering affordable biologics to emerging markets.
View full company profileTherapeutic Areas
Other Autoimmune diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Humira (Adalimumab) Biosimilar | NeuClone | Early Preclinical |
| HBM7020 | Harbour BioMed | Discovery |
| R2006 | Harbour BioMed | Discovery |
| R7027 | Harbour BioMed | Discovery |
| ImmCelz™ Platform | Creative Medical Technology Holdings | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Gavocabtagene autoleucel | astellas | Phase 1/2 |
| TYK-101 | TYK Medicines | Phase 1 |
| HCB206 | HanchorBio | Preclinical |
| miR-124 Activator | Formation Bio | Phase 2 |
| Autologous Cell Therapy Collaboration | Lupagen | Preclinical |
| Autoimmune Diagnostics Leadership Initiative | Vibrant America Clinical Laboratory | Commercial |